Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity.

Abstract

OBJECTIVE:

This study aimed to compare the efficacy of long-acting risperidone and zuclopenthixol in subjects with schizophrenia and substance abuse.

METHOD:

A total of 115 subjects with schizophrenia and substance use disorders were enrolled for an open, randomized, controlled, 6-month follow-up study. Fifty-seven subjects were selected for treatment with long-acting injectable risperidone, while another 58 were treated with zuclopenthixol-depot.

RESULTS:

Long-acting risperidone patients presented fewer positive urine tests (8.67 compared with 10.36, P = 0.005), showed improved scores on the Positive and Negative Syndrome Scale, and showed better compliance with the Substance Abuse Management program. The use of long-acting risperidone and less severe dependence explained the outcome at the end of the follow-up.

CONCLUSIONS:

Long-acting injectable risperidone was more effective than zuclopenthixol-depot in improving substance abuse and schizophrenia symptoms in subjects with dual diagnosis.

• Authors: Gabriel Rubio, Isabel Martínez, Guillermo Ponce, Miguel Angel Jiménez-Arriero, Francisco López-Muñoz, Cecilio Alamo
• Journal: Canadian journal of psychiatry. Revue canadienne de psychiatrie (Can J Psychiatry) Vol. 51 Issue 8 Pg. 531-9 (Jul 2006) ISSN: 0706-7437 [Print] United States
• PMID: 16933590 (Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Antipsychotic Agents
• Delayed-Action Preparations
• Clopenthixol
• Risperidone

Topics

• Adolescent
• Adult
• Aged
• Antipsychotic Agents (administration & dosage, therapeutic use)
• Clopenthixol (therapeutic use)
• Comorbidity
• Delayed-Action Preparations (therapeutic use)
• Double-Blind Method
• Female
• Follow-Up Studies
• Humans
• Injections, Intravenous
• Male
• Middle Aged
• Risperidone (administration & dosage, therapeutic use)
• Schizophrenia (drug therapy, epidemiology)
• Substance-Related Disorders (epidemiology)